GET DAILY SIGNALSKrystal Biotech (KRYS): Analyst Targets Point to +20% Upside Toward $400
Key Takeaways
- The central $400 target is the arithmetic mean of eight verifiable, current analyst price targets on Krystal Biotech, rounded from roughly $397.
- The latest verified share price is about $332, meaning reaching $400 would require a move of roughly 20%—a substantial, though not extreme, advance.
- Individual analyst targets span a wide $284 to $474 range, reflecting sharply different assumptions about pipeline and commercial execution.
- The strongest supports are growing revenue from the lead gene therapy Vyjuvek, an expanding international launch, and a deep clinical pipeline.
- The biggest risks are heavy reliance on a single product, unpredictable patient treatment patterns, reimbursement pressure, and binary clinical outcomes.
- Krystal Biotech is a commercial-stage gene therapy company, not an ETF, so this analysis centers on analyst price targets and company fundamentals.
- Readers can explore more detail on Major News, Today's Price Move, a Forecast, and Earnings for KRYS.
Analyst Price Targets and Consensus View
Krystal Biotech, Inc. (KRYS) carries a "Strong Buy" consensus rating from sell-side analysts. This central target is not a copied headline figure; it was calculated from eight individual, attributable targets reviewed for this analysis. The set spans roughly $284 to $474, with a simple arithmetic mean of about $397, rounded to a clean $400 central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent revisions cluster toward the upper half of the range. Citigroup raised its target to $416 from $386 in October 2026 after a clinical update, while Goldman Sachs resumed coverage with a $441 target in September. TD Cowen holds a $403 target, RBC Capital initiated at $400, and BofA raised its target to $400 from $392. Jefferies sits at the top with $474, while Guggenheim's $284 marks the low end, and H.C. Wainwright holds $361.
The wide dispersion reflects genuine disagreement: bullish analysts weight expanding commercial uptake and pipeline optionality, while cautious ones discount execution and pricing risk. The mean is a statistical summary, not a guarantee or an official published consensus.
Current Market Position and Path Toward the Target
With shares near $332, reaching $400 requires an approximate 20% upside—a substantial move by any measure. The stock has already re-rated meaningfully from a 52-week low around $137, reflecting a market cap near $9.8 billion as the company transitions from an early commercial launch to a multi-product, multi-market gene therapy franchise.
The path toward $400 would most plausibly rely on sustained revenue growth rather than multiple expansion alone. Krystal reported quarterly revenue of about $119 million for the period ending June 30, 2026, up from roughly $96 million a year earlier, with net profit also rising. International launches in Germany, France, and Japan, a UK marketing authorization secured in May 2026, and a planned Italy launch add incremental geographic runway. Continued clinical progress on programs such as the cystic fibrosis candidate KB407 and the alpha-1 antitrypsin deficiency candidate KB408 could justify higher valuations.
What Could Support a Move Toward the Target
- Vyjuvek momentum: the lead therapy for dystrophic epidermolysis bullosa has shown durable uptake, with over 660 U.S. reimbursement approvals and expanding international demand.
- Pipeline optionality: registrational-stage programs across cystic fibrosis, alpha-1 antitrypsin deficiency, ophthalmology, and oncology broaden the growth story beyond one drug.
- Analyst revisions: most recent target changes have been upward, and the stock was added to the S&P MidCap 400 index, a catalyst for institutional index demand.
- Balance sheet strength: the company held roughly $956 million in cash and investments at the end of fiscal 2025, funding research without immediate dilution pressure.
What Could Prevent the Target From Being Reached
- Single-product concentration: revenue remains heavily dependent on Vyjuvek, so any slowdown in patient starts or treatment persistence directly pressures results.
- Quarterly volatility: the chronic and variable nature of dystrophic epidermolysis bullosa leads to treatment pauses and restarts, reducing revenue predictability.
- Pricing and reimbursement: intensifying global pricing scrutiny on orphan and gene therapies could compress margins as the company expands internationally.
- Binary clinical risk: setbacks or delays in pipeline readouts could remove the very optionality underpinning the highest analyst targets.
Technical Levels and Market Structure
The stock trades below its 52-week high near $382.54, which sits between the current price and the $400 target and therefore represents a key near-term resistance zone. The $400 level itself is also a psychological round-number marker that may attract selling interest. The shares remain in a long-term uptrend off the 52-week low near $137, but the wide gap between the current price and that low underscores how far the stock has already traveled.
Time Horizon and What Investors Should Monitor
Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms apply different assumptions and update timing. Investors should watch quarterly earnings and Vyjuvek revenue trends, reimbursement decisions in new European markets, and upcoming clinical readouts for KB407 and KB408. Changes in analyst targets—especially any move away from the recent upward revision pattern—would be an important signal, as would shifts in sector-wide sentiment toward gene therapy valuations. From what I see, tracking these elements closely helps clarify the path ahead.
Using AI Daily Buy/Sell Signals for Additional Perspective
As part of my routine analysis, I find Tickeron's AI Daily Buy/Sell Signals helpful for layering data-driven insights onto fundamental work. These signals use artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. They allow users to spot opportunities and track trends more efficiently, providing an objective complement to reviewing analyst targets and company developments.
Putting It All Together
The $400 target represents a roughly 20% move from the current price near $332, built from the mean of eight verified analyst targets spanning $284 to $474. The case for reaching that level rests on continued Vyjuvek growth, international expansion, and pipeline progress, while the case against it hinges on single-product dependence, treatment-pattern volatility, reimbursement risk, and binary clinical outcomes. The unusually wide target range shows analysts genuinely disagree about how much of the pipeline to price in today. Whether KRYS closes the gap will depend most on execution in commercial markets and upcoming data readouts—outcomes that no price target can promise in advance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KRYS sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for KRYS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 45 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 259 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 83 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 42 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
KRYS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for KRYS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.444) is normal, around the industry mean (3.104). P/E Ratio (35.780) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company which provides therapies for rare and orphan diseases
Industry Biotechnology
Advertisement